Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fludarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | NT5E | P21589 | 2/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.52 |
| ▸ | FPR2 | P25090 | 2/20 | 0.52 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.52 |
| ▸ | DTYMK | P23919 | 2/20 | 0.52 |
| ▸ | PNP | P00491 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine Phosphate SCHEMBL27849470 | 0.92 | CA5A (0.68) | LMNANT5EHIF1ASMN1; SMN2CA5A | |
| Fludarabine Phosphate SCHEMBL28143246 | 0.92 | CA5A (0.67) | LMNANT5EHIF1ASMN1; SMN2CA5A | |
| Fludarabine Phosphate SCHEMBL28142252 | 0.87 | CA5A (0.59) | LMNANT5EHIF1ASMN1; SMN2CA5A | |
| Fludarabine SCHEMBL1674414 | 0.86 | NT5E (0.62) | LMNANT5EHIF1ACA5ADTYMK | |
| Fludarabine SCHEMBL4455725 | 0.85 | LMNA (0.47) | LMNANT5EHIF1ASMN1; SMN2CA5A | |
| Fludarabine Phosphate SCHEMBL20899648 | 0.85 | CA5A (0.66) | LMNANT5EHIF1ASMN1; SMN2CA5A | |
| 5-Fluorouridine SCHEMBL4390962 | 0.83 | LMNA (0.83) | LMNANT5ESMN1; SMN2 | |
| 5-Fluorouridine SCHEMBL4390966 | 0.83 | LMNA (0.83) | LMNANT5ESMN1; SMN2 | |
| Fludarabine SCHEMBL8934950 | 0.83 | LMNA (0.76) | LMNANT5EHIF1ASMN1; SMN2CA5A | |
| Fludarabine SCHEMBL1697072 | 0.83 | LMNA (0.76) | LMNANT5EHIF1ASMN1; SMN2CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11890276-B2 | Methods of treating pancreatic cancer | CHEMOCENTRYX, INC. (US) | 2024-02-06 | — | — | US | claimed |
| WO-2023194441-A1 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2023-10-12 | — | — | WO | claimed |
| CN-109053595-B | Salts of epidermal growth factor receptor kinase inhibitors | 西建卡尔有限责任公司 | 2022-04-01 | — | — | CN | claimed |
| US-20210401816-A1 | METHODS OF TREATING PANCREATIC CANCER | CHEMOCENTRYX, INC. | 2021-12-30 | — | — | US | claimed |
| EP-3297438-B1 | CCR2 MODULATORS | CHEMOCENTRYX INC (US) | 2021-10-20 | — | — | EP | claimed |
| US-11116756-B2 | Methods of treating pancreatic cancer | CHEMOCENTRYX, INC. (US) | 2021-09-14 | — | — | US | claimed |
| CN-108135168-B | CCR2 modulators | 凯莫森特里克斯股份有限公司 | 2021-07-20 | — | — | CN | claimed |
| US-20200179359-A1 | METHODS OF TREATING PANCREATIC CANCER | CHEMOCENTRYX, INC. | 2020-06-11 | — | — | US | claimed |
| US-10583131-B2 | Methods of treating pancreatic cancer | CHEMOCENTRYX, INC. (US) | 2020-03-10 | — | — | US | claimed |
| US-20190350911-A1 | METHODS OF TREATING PANCREATIC CANCER | CHEMOCENTRYX, INC. | 2019-11-21 | — | — | US | claimed |
| EP-2155177-A2 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | Intezyne Technologies Incorporated (US) | 2010-02-24 | — | — | EP | claimed |
| US-7638558-B2 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-12-29 | — | — | US | claimed |
| EP-1907444-B1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES INC (US) | 2009-08-19 | — | — | EP | claimed |
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | US | claimed |
| US-20090098200-A1 | COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION | SOLUBEST LTD. (IL) | 2009-04-16 | — | — | US | claimed |
| WO-2009040818-A1 | COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION | SOLUBEST LTD (IL) | 2009-04-02 | — | — | WO | claimed |
| WO-2008134761-A2 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| EP-1907444-A2 | POLYMERIC MICELLES FOR DRUG DELIVERY | Intezyne Technologies Incorporated (US) | 2008-04-09 | — | — | EP | claimed |
| US-20060240092-A1 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | INTEZYNE TECHNOLOGIES, INC. | 2006-10-26 | — | — | US | claimed |
| WO-2006107903-A2 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179359-A1 | METHODS OF TREATING PANCREATIC CANCER | RNASE1, KRAS, PNLIP | LMNA 4359/4885NT5E 2108/4885HIF1A 1570/4885 |
| US-20190350911-A1 | METHODS OF TREATING PANCREATIC CANCER | RNASE1, KRAS, PNLIP | LMNA 4359/4885NT5E 2108/4885HIF1A 1570/4885 |
| US-11116756-B2 | Methods of treating pancreatic cancer | RNASE1, KRAS, PNLIP | LMNA 4359/4885NT5E 2108/4885HIF1A 1570/4885 |
| US-20210401816-A1 | METHODS OF TREATING PANCREATIC CANCER | RNASE1, KRAS, PNLIP | LMNA 4359/4885NT5E 2108/4885HIF1A 1570/4885 |
| US-20060240092-A1 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | ABCB1, TERT, ABCB4 | LMNA 1309/4885NT5E 4389/4885HIF1A 3482/4885 |
| US-11890276-B2 | Methods of treating pancreatic cancer | RNASE1, KRAS, PNLIP | LMNA 4359/4885NT5E 2108/4885HIF1A 1570/4885 |
| US-20090110662-A1 | MODIFICATION OF BIOLOGICAL TARGETING GROUPS FOR THE TREATMENT OF CANCER | CD44, CD47, EPCAM | LMNA 3626/4885NT5E 709/4885HIF1A 1250/4885 |
| US-10583131-B2 | Methods of treating pancreatic cancer | RNASE1, KRAS, PNLIP | LMNA 4359/4885NT5E 2108/4885HIF1A 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.